BioSpace News Archive

Young Woman Standing In Front Of Exit Door. Full Length, Vector, Illustration, Flat Design, Character.

Layoffs

Relay Therapeutics to Lay Off 10% of Workforce

Relay Therapeutics is cutting its workforce to help streamline its research organization as it looks to complete its first large-scale, pivotal clinical trial.

October 4, 2024

·

1 min read

·

Angela Gabriel

Update: AbbVie headquarters building in California

Earnings

AbbVie Trims Full-Year Earnings Guidance Due to R&D Milestone Costs

The company is lowering its previously issued guidance for 2024 adjusted earnings per share by $0.04 per share to account for acquired in-process research and development expenses incurred for acquisitions and collaborations in the third quarter.

October 4, 2024

·

1 min read

·

Tristan Manalac

Pictured: Blue Sanofi sign on building in Germany at night

Rare diseases

Sanofi Offloads Rare Autoimmune Drug to Recordati in Potential $1B Deal

Under the deal announced Friday, the Italian pharma will make an upfront payment of $825 million to Sanofi for global rights to a biologic for the treatment of cold agglutinin disease, with milestone payments of up to $250 million.

October 4, 2024

·

2 min read

·

Tristan Manalac

Central Coast New South Wales Australia – May 21, 2024 Assortment of weight loss and diabetic drugs on the table

Editorial

Obesity Drug Shortage Ends for Lilly, Continues for Novo as Industry Bolsters Manufacturing

Scaling GLP-1 manufacturing capacity remains a key priority for the pharma industry, to help supply catch up with the insatiable demand for weight loss drugs.

October 4, 2024

·

3 min read

·

Greg Slabodkin

Pictured: BMS sign on a building in San Diego, California/iStock, JHVEPhoto

Approvals

BMS Wins FDA Nod for Perioperative Opdivo Regimen in NSCLC

Opdivo’s approval for patients with resectable non-small cell lung cancer comes as the regulator recently raised concerns of overtreatment with this type of therapeutic regimen with platinum-doublet chemotherapy.

October 4, 2024

·

2 min read

·

Tristan Manalac

Gloved hand holding a vial of mpox vaccine

Vaccines

Bavarian Nordic’s Mpox Shot Shows Antibody Responses Wane After 6 to 12 Months: Study

While a JAMA study found a decline in mpox antibody responses after vaccination, a University of Oxford expert cautioned that there is still not enough evidence to determine if this decline also leads to waning protections.

October 4, 2024

·

2 min read

·

Tristan Manalac

Press Releases

Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant Exercise

October 4, 2024

·

2 min read

Press Releases

Bavarian Nordic Joins Global Efforts to Fight Mpox Outbreak in Africa